Epigenetic therapies represent a promising disease-modifying approach for Parkinson's disease (PD) by targeting the epigenetic dysregulation that contributes to neurodegeneration. These interventions aim to restore normal gene expression patterns through DNA methylation, histone modifications, and chromatin remodeling.
Multiple epigenetic alterations have been identified in PD brains:
- DNA methylation changes: Decreased global DNA methylation in the substantia nigra, with hypermethylation of specific genes including SNCA promoter region
- Histone modifications: Altered histone acetylation and methylation patterns affecting transcriptional regulation of PD-relevant genes
- Chromatin remodeling: Dysregulated chromatin states contributing to mitochondrial dysfunction and neuroinflammation
DNA methylation inhibitors can reverse aberrant methylation patterns:
| Agent |
Mechanism |
Development Stage |
Target |
| 5-azacytidine |
DNA methyltransferase inhibitor |
Preclinical |
Global hypomethylation |
| Zebularine |
DNMT inhibitor |
Preclinical |
SNCA methylation |
| FGI-104 |
Small molecule DNMT inhibitor |
Research |
Neuroprotection |
HDAC inhibitors restore histone acetylation balance and gene expression:
| Agent |
HDAC Target |
Development Stage |
Reference |
| Valproic acid |
Class I HDACs |
Clinical trials (NCT00538356) |
PMID:18403658 |
| vorinostat (SAHA) |
Class I/II HDACs |
Preclinical |
PMID:23954641 |
| LBH589 (Panobinostat) |
Class I/II/III HDACs |
Preclinical |
PMID:25849638 |
| RGFP109 |
HDAC1/3 selective |
Preclinical |
PMID:26202845 |
Activating HATs can increase beneficial gene expression:
- CSP-TTK-I-3B: P300/CBP activator showing neuroprotective effects
- Pentadecylidene): Natural compound with HAT-activating properties
Targeting chromatin remodeling complexes:
| Target |
Function |
Therapeutic Approach |
| BRG1 (SMARCA4) |
SWI/SNF complex |
Activation for neuroprotection |
| BAF complexes |
Neuronal differentiation |
Modulation for regeneration |
| NuRD complex |
Transcriptional repression |
Inhibition |
-
Valproic Acid: Safety trial in PD patients (NCT00538356)
- Showed acceptable safety profile
- Preliminary evidence of motor symptom improvement
-
Phenylbutyrate: Tested for neuroprotection
flowchart TD
A["HDAC Inhibitor"] --> B["Increased H3K9ac at BDNF promoter"]
B --> C["Enhanced BDNF expression"]
C --> D["Increased neuron survival"]
A --> E["Reduced alpha-synuclein aggregation"]
E --> F["Improved mitochondrial function"]
D --> G["Motor improvement in PD models"]
F --> G
- Mitochondrial biogenesis: PGC-1α activation via epigenetic mechanisms
- Anti-inflammatory: Reduced neuroinflammation through chromatin-level regulation
- Anti-aggregative: Decreased SNCA expression and aggregation
- Anti-oxidative: Upregulation of antioxidant genes (NFE2L2, SOD1)
| Gene/Region |
Epigenetic Change |
Therapeutic Target |
| SNCA promoter |
Hypermethylation |
Demethylation |
| PARK2 (Parkin) |
Hypomethylation |
Methylation |
| BDNF promoter |
Reduced acetylation |
HDAC inhibition |
| NFE2L2 |
Repressed chromatin |
HAT activation |
| IL-1β |
Hypomethylation |
Anti-inflammatory |
Epigenetic therapies show synergy with:
- LDOPA: HDAC inhibitors enhance dopaminergic function
- Physical exercise: Epigenetic modifications complement motor benefits
- GDNF: Chromatin remodeling enhances neurotrophic factor expression
¶ Challenges and Considerations
- Many HDAC inhibitors have limited CNS penetration
- Novel formulations (liposomal, nanoparticle) in development
- Focus on brain-penetrant compounds (vorinostat alternatives)
- Global epigenetic modifications may cause unwanted gene expression changes
- Tissue-specific delivery approaches being developed
- Dose-optimization critical for safety
- Epigenetic changes must be carefully titrated
- Reversibility of modifications both advantage and concern
| Company/Institution |
Compound |
Target |
Stage |
| Neuro epigenetic Inc |
NEI-001 |
HDAC |
Preclinical |
| Cerevel |
CVL-231 |
HDAC1/2 |
Phase 1 |
| University of Pennsylvania |
HDACi-7 |
Class I HDAC |
Preclinical |
- Jowaed A, et al. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease brains. J Neurosci. 2010;30(18):6355-6359
- Harrison IF, et al. Histone deacetylase inhibitors as therapeutic agents for Parkinson's disease. Front Cell Neurosci. 2020
- Packer MS, et al. CRISPR-Cas9 epigenome editing for Alzheimer's and Parkinson's disease. Nat Rev Neurol. 2024
- Kontopoulos E, et al. Alpha-synuclein in Parkinson's disease: an epigenetic perspective. J Parkinsons Dis. 2021
- Gao F, et al. Epigenetic regulation in Parkinson's disease. Mol Neurobiol. 2023
- Cheng D, et al. Histone deacetylase (HDAC) inhibitors: a promising therapeutic strategy for Parkinson's disease. Curr Neuropharmacol. 2023